GLP-1 therapy can lower A1C meaningfully: clinical trial data from the SUSTAIN program showed average reductions of 1.01.8 percentage points with semaglutide, depending on dose and baseline.[3] If a patient is also on insulin or a sulfonylurea, a significant A1C drop can create hypoglycemia risk that warrants co-medication adjustment
Tirzepatide vial (lyophilized powder, check the mg amount on the label) Bacteriostatic water (not sterile water, not saline, not tap water) Insulin syringes (U-100, choose 0.5mL or 1.0mL based on your water volume) Alcohol swabs (70% isopropyl alcohol prep pads) Clean, flat surface (disinfected with alcohol wipe) A note on water types for peptide mixing : bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth and allows the vial to be used over multiple doses across up to 28 days
Write it down
Targeted probiotics are another option for improving gut health and GLP-1 production
Researchers may use intravenous infusion, defined timing, strict observation, and selected participants
